pixitmedia, a Kalray Subsidiary, Supports Amazon Web Services’ Media & Entertainment Creation Lifecycle Demonstrations at IBC 2022
20.9.2022 10:04:00 EEST | Business Wire | Press release
pixitmedia1, a Kalray company, has announced today that pixstor™ and ngenea® (a shared storage and data orchestration solution) will be included in the content production area at the Amazon Web Services (AWS) stand (5.C80) at IBC 2022.
AWS will be showcasing a suite of end-to-end cloud production workflows, demonstrating how the industry’s leading tools for editing, compositing, finishing, grading and quality control (QC) can be used for full production in the cloud. These workflows will be supported by pixitmedia’s flagship products, pixstor and ngenea, software-defined storage and orchestration software.
This follows the announcement that pixitmedia has been accepted into the AWS Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS.
Offline editorial, visual effects (VFX) and color grading work is not only possible in the cloud, but can deliver huge and tangible benefits in performance, collaboration, scalability, and cost efficiencies for producers.
At IBC stand 5.C80, AWS will demonstrate the media creation lifecycle in five stages. Live camera footage will be ingested to a cloud collaborative environment using dailies platform Moxion. That footage will be edited in Adobe® Premiere® Pro and conformed in Flame®, Autodesk®'s finishing and VFX solution. A fourth stage will demonstrate FilmLight Baselight performing the color grade, and finally, the content will pass through Colorfront Streaming and Broker Service for QC, which also reads directly from Amazon S3.
The high-resolution, uncompressed 4K media for all five stages of the production process will be edited in place on the powerful media-centric storage infrastructure powered by pixstor and ngenea, with 10-bit uncompressed video streamed from applications running in the cloud to the stand. It will use the latest AWS Cloud Digital Interface (AWS CDI), NewTek Network Device Interface (NDI), and Colorfront Streaming and Broker Service technology, over a secure internet connection to an Amazon VPC. Amazon EC2 compute, Amazon Elastic Block Store and Amazon S3 storage underpin the entire pixstor and ngenea solution.
Ben Leaver, EVP of Business Development and Co-Founder of pixitmedia explains:
“We’re looking forward to being featured in the AWS stand at IBC to showcase our storage and data orchestration platform to the Media & Entertainment industry. Together with AWS and industry-standard software providers, we will demonstrate that high-end editorial, VFX and color grading work is possible in the cloud today. We are providing our customers with ease of use, guaranteed performance, greater collaboration and seamless workflows in the cloud.”
pixitmedia is a global member of the AWS Partner Network (APN) and an industry facilitator of cloud-enabled production workflows. pixstor offers AWS customers an agile storage environment that guarantees adaptability and performance. Coupled with the power of pixitmedia’s ngenea, it quickly and securely transports data to and from globally distributed cloud, object storage, and traditional network attached storage (NAS).
To learn more about pixitmedia at IBC 2022, click here
About pixitmedia
pixitmedia is a Kalray company (Euronext, ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge. pixitmedia and Kalray share a common vision and a complementary value proposition in both software and hardware to address today’s and tomorrow’s data-intensive world with solutions for a more intelligent, effective, energy-wise and user-friendly data-driven world.
pixitmedia facilitates seamless collaboration to enable the power of ideas. Our award-winning purpose-built, software-defined storage and data solutions simplify the flow of data to connect an increasingly complex world. Our aim is to deliver beyond expectations throughout all areas of our operation. We devise optimized solutions that give customers both choice and freedom, our restless innovation constantly pushes boundaries and the unrivalled care and knowledge of our team ensure optimum performance and value. Customer success is at the heart of our business, we have technical specialists and a unique, dedicated lab facility to guarantee the effectiveness of our solutions.
For more information, please visit: https://www.pixitmedia.com or email: marketing@pixitmedia.com
About Kalray
Kalray (Euronext Growth Paris - ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance,
data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and data center infrastructures.
Kalray’s offerings include its unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as its leading-edge
software-defined storage and data management offers. Individually or combined, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: more for a smart world, more for the planet, more for customers and developers. https://www.kalrayinc.com
1 pixitmedia is the dedicated branch for Media & Entertainment markets of arcapix Holdings Ltd, acquired by Kalray. See press release on March 3, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005287/en/
Contact information
Email: marketing@pixitmedia.com
Tel: 07539 823415
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom